HuGE Literature Finder
Records 1-5
|
Phase 1/2 study of rilotumumab (AMG 102), a hepatocyte growth factor inhibitor, and erlotinib in patients with advanced non-small cell lung cancer.
Cancer 2017 Aug 123 (15): 2936-2944. Tarhini Ahmad A, Rafique Imran, Floros Theofanis, Tran Phu, Gooding William E, Villaruz Liza C, Burns Timothy F, Friedland David M, Petro Daniel P, Farooqui Mariya, Gomez-Garcia Jose, Gaither-Davis Autumn, Dacic Sanja, Argiris Athanassios, Socinski Mark A, Stabile Laura P, Siegfried Jill |
|
Tumor and circulating biomarkers in patients with second-line hepatocellular carcinoma from the randomized phase II study with tivantinib.
Oncotarget 2016 Aug . Rimassa Lorenza, Abbadessa Giovanni, Personeni Nicola, Porta Camillo, Borbath Ivan, Daniele Bruno, Salvagni Stefania, Van Laethem Jean-Luc, Van Vlierberghe Hans, Trojan Jörg, De Toni Enrico N, Weiss Alan, Miles Steven, Gasbarrini Antonio, Lencioni Monica, Lamar Maria E, Wang Yunxia, Shuster Dale, Schwartz Brian E, Santoro Arman |
|
Clinical usefulness of gefitinib for non-small-cell lung cancer with a double epidermal growth factor receptor mutation.
Molecular and clinical oncology 2015 Mar 3 (2): 329-333. Oikawa Takefumi, Ohira Tatsuo, Otani Keishi, Hagiwara Masaru, Konaka Chimori, Ikeda Norihi |
|
Association between plasma hepatocyte growth factor and gefitinib resistance in patients with advanced non-small cell lung cancer.
Lung cancer (Amsterdam, Netherlands) 2011 Nov 74 (2): 293-9. Han Ji-Youn, Kim Jin Young, Lee Suk Hyung, Yoo Nam Jin, Choi Byung G |
|
Somatic mutation and functional polymorphism of a novel regulatory element in the HGF gene promoter causes its aberrant expression in human breast cancer.
The Journal of clinical investigation 2009 Mar 119 (3): 478-91. Ma Jihong, DeFrances Marie C, Zou Chunbin, Johnson Carla, Ferrell Robert, Zarnegar Re |
- Page last reviewed:Oct 1, 2020
- Page last updated:Jun 16, 2021
- Content source: